ArticleCancer management and research2018
Prognostic factors for survival among patients with primary bone sarcomas of small bones.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Prognostic factors and survival outcomes in patients undergoing limb-sparing surgery for primary malignant bone tumors.Frontiers in oncology · 2026Article
- Epidemiology and Chemosensitivity of Primary Malignant Bone Tumors at a Teaching Hospital in South Africa: A 5-Year Retrospective Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Prognostic analysis and clinical characteristics of osteosarcoma and Ewing sarcoma of the rib, sternum, and clavicle: a SEER-based study.The Journal of international medical research · 2023Article
- Patterns and Trends of the Mortality From Bone Cancer in Pudong, Shanghai: A Population-Based Study.Frontiers in oncology · 2022Article
- Survival Analysis in Gastrointestinal Neuroendocrine Carcinoma With Bone Metastasis at Diagnosis.Frontiers in surgery · 2022Article
- Establishing a novel prognostic tool for Ewing sarcoma patients: Surveillance, Epidemiology, and End Results database analysis.Medicine · 2020Article
- microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis.Journal of experimental & clinical cancer research : CR · 2020Article
- Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement.Acta orthopaedica et traumatologica turcica · 2020Article
- Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation.Annals of translational medicine · 2020Article
- Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015.BMC musculoskeletal disorders · 2020Article
- Establishment and Validation of Novel Clinical Prognosis Nomograms for Luminal A Breast Cancer Patients with Bone Metastasis.BioMed research international · 2020Article
- Identifying the Prognosis Factors and Predicting the Survival Probability in Patients with Non-Metastatic Chondrosarcoma from the SEER Database.Orthopaedic surgery · 2019Article
- A nomogram for determining the disease-specific survival in Ewing sarcoma: a population study.BMC cancer · 2019Article
- Development and validation of a nomogram for osteosarcoma-specific survival: A population-based study.Medicine · 2019Article
- Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma.Frontiers in oncology · 2019Article
- Marital Status and Survival of Patients with Chondrosarcoma: A Population-Based Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Nomogram application to predict overall and cancer-specific survival in osteosarcoma.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary bone sarcomas of the hands or feet are rare lesions and poorly documented. Moreover, the prognostic determinants of bone sarcomas of the hands or feet have not been reported. MATERIALS AND
methodsThe Surveillance, Epidemiology, and End Results (SEER) program database was used to screen patients with bone sarcomas of the hands or feet from 1973 to 2013, with attention paid to chondrosarcoma, Ewing sarcoma, and osteosarcoma. The prognostic values of overall survival (OS) and cancer-specific survival (CSS) were assessed using Cox proportional hazards regression model with univariate and multivariate analyses. The Kaplan-Meier method was used to obtain OS and CSS curves.
resultsA total of 457 cases were selected from the SEER database. Chondrosarcoma was the most common form of lesion in hands or feet or both, followed by Ewing sarcoma and osteosarcoma. The 5- and 10-year OS rates of the entire group were 75.7% and 66.1%, respectively. The 5- and 10-year CSS rates were 78.7% and 73.7%, respectively. Multivariate analysis revealed that age under 40 years, localized stage, low grade, surgical treatment, and first primary tumor were associated with improved OS, and decade of diagnosis, stage, grade, and surgery were independent predictors of CSS. However, no significant differences were observed in OS and CSS among patients with different primary tumor locations and tumor subtypes. Additionally, the most significant prognostic factor was whether metastasis had occurred at the time of initial diagnosis.
conclusionAmong patients with primary bone sarcomas of the hands or feet, younger age (<40 years), localized stage, low grade, surgical treatment, and first primary tumor are favorable factors for prolonging survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.